Joseph Papa confirms position day after he resigns from the top spot at drugmaker Perrigo

Iseq rises as stocks on Wall Street and in Europe lifted by energy companies

Canadian pharma company says it remains well positioned to meet its obligations

New rules on corporate inversions see parties turn their attention elsewhere

Sprout shareholders say company has set price too high, not marketing pill properly

Pharmaceutical giant faces a growing list of questions from investors and regulators

Company has appointed activist investor William Ackman to its board

Iseq ends lower with Bank of Ireland, Applegreen and Aryzta among the fallers

The Canadian drugmaker cut its 2016 forecast by about 12% causing shares to plunge

Canadian drugmaker cuts its revenue forecast by 12% and raises the spectre of default

Deb Jorn oversaw the Canadian pharmaceutical’s US dermatology business

News comes as Canadian drug-maker pulled 2016 forecasts

Chief executive back at the helm after two-month absence through illness but Robert Ingram retains chairman’s post

First damages award over claims firm knew of ovarian cancer risks decades ago, company still faces 1,200 suits

Wall Street Journal reports that pharmaceutical firm plans to restate earnings

Hospitalisation of Mike Pearson saw firm split his roles and bring Ingram to the chair

Pershing Square Capital increased stake in beleaguered drug group last November but acts to generate tax loss for investors

Pharma companies’ method of buying drug makers and racking up costs is a threat to R&D

Food group Aryzta’s shares drop again in Dublin following boardroom reshuffle

Eye-popping growth and questionable acquisitions raise far too many questions